CCG
CRL icon

Cypress Capital Group’s Charles River Laboratories CRL Stock Holding History

Cypress Capital Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-888
Closed -$241K – 298
2024
Q1 		$241K Sell
888
-10
-1% -$2.39K 0.03% 274
2023
Q4 		$212K Buy
+898
New +$177K 0.03% 286
2023
Q3 		– Sell
-956
Closed -$201K – 299
2023
Q2 		$201K Sell
956
-94
-9% -$18.7K 0.03% 293
2023
Q1 		$212K Buy
+1,050
New +$238K 0.03% 280

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Cypress Capital Group's CRL Position: Q2 2024 in Review

Cypress Capital Group sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 888 shares — an estimated $241K sold.

Cypress Capital Group first reported a position in CRL in Q1 2023 and held it in 4 quarters. The position peaked at $241K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Cypress Capital Group reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Cypress Capital Group sold 888 Charles River Laboratories shares in Q2 2024, an estimated $241K.
  • Cypress Capital Group first reported a position in Charles River Laboratories in Q1 2023 and held it in 4 quarters.
  • Cypress Capital Group's Charles River Laboratories position peaked at $241K in Q1 2024.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Cypress Capital Group's 13F filing for Q2 2024, filed 25 Jul 2024.